Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–12 of 12 results
Advanced filters: Author: Bernat Olle Clear advanced filters
  • A group of microbiome researchers discuss some of the challenges in developing a new generation of microbiome therapies.

    • Gaspar Taroncher-Oldenburg
    • Susan Jones
    • Jun Wang
    Special Features
    Nature Biotechnology
    Volume: 36, P: 1037-1042
  • Strain richness of gut microbiota ecosystems is a key characteristic underpinning engraftment in faecal microbiota transplantation, and could improve the design of defined live biotherapeutic products with predictable outcomes.

    • Alice Chen-Liaw
    • Varun Aggarwala
    • Jeremiah J. Faith
    Research
    Nature
    Volume: 637, P: 422-429
  • Transplants of consortia with limited numbers of strains of commensal bacteria derived from healthy human stool samples are able to suppress intestinal Enterobacteriaceae by regulating gluconate availability, suggesting potential therapies for infectious and inflammatory diseases.

    • Munehiro Furuichi
    • Takaaki Kawaguchi
    • Kenya Honda
    ResearchOpen Access
    Nature
    Volume: 633, P: 878-886
  • Colonization of trypsin-degrading commensal bacteria may contribute to the maintenance of intestinal homeostasis and protection against pathogen infection in humans and mice.

    • Youxian Li
    • Eiichiro Watanabe
    • Kenya Honda
    ResearchOpen Access
    Nature
    Volume: 609, P: 582-589
  • A consortium of 11 bacterial strains from the healthy human gut microbiota can strongly induce interferon-γ-producing CD8 T cells in the intestine, and enhance both resistance to bacterial infection and the therapeutic efficacy of immune checkpoint inhibitors.

    • Takeshi Tanoue
    • Satoru Morita
    • Kenya Honda
    Research
    Nature
    Volume: 565, P: 600-605
  • Five years after the launch of the Human Microbiome Project, several ventures are seeking to capitalize on the clinical promise of microbiome modulation. Commercialization of drugs that influence the human flora poses some unique scientific, translational and regulatory challenges.

    • Bernat Olle
    Special Features
    Nature Biotechnology
    Volume: 31, P: 309-315
  • This study identifies 17 strains of human-derived Clostridia capable of inducing the accumulation and functional maturation of regulatory T cells; it is suggested that these strains may be useful candidates for the future development of oral bacterial therapeutics to treat human inflammatory disorders.

    • Koji Atarashi
    • Takeshi Tanoue
    • Kenya Honda
    Research
    Nature
    Volume: 500, P: 232-236